PitchSend

Investor Presentaiton

Investor presentation Full year 2018 Slide 63 Solid TresibaⓇ performance strengthens basal insulin market share in Japan Japanese basal value market shares TresibaⓇ NPH LevemirⓇ glargine U100 - biosimilar glargine U100 Japanese total insulin value market shares Eli Lilly glargine U300 -- - NN Total Basal 80% - Novo Nordisk Sanofi 70% 60% 50% 40% 30% 20% 10% 0% Nov 2015 Source: IQVIA monthly MAT Nov, 2018 value figures NPH: Novolin® changing diabetes 60% -51% 44% 40% 18% -14% 20% 14% 6% 2% 0% Nov 2018 Nov 2015 Source: IQVIA monthly MAT Nov, 2018 value figures, numbers do not add up to 100% due to smaller insulin manufacturers 59% 22% 18% Nov 2018 novo nordisk

View entire presentation